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Available online xxxxBackground: Red cell distribution width (RDW) is a standard component of the automated blood count, and is of
prognostic value in heart failure and coronary heart disease. We investigated the association between RDW and
cardiovascular events in patients with adult congenital heart disease (ACHD).
Methods and results: In this prospective cohort study, 602 consecutive patients with ACHDwho routinely visited
the outpatient clinic were enrolled between 2011 and 2013. RDWwas measured in fresh venous blood samples
at inclusion in 592 patients (median age 33 [IQR 25–41] years, 58%male, 90% NYHA I) and at four annual follow-
up visits. During 4.3 [IQR 3.8–4.7] years of follow-up, the primary endpoint (death, heart failure, hospitalization,
arrhythmia, thromboembolic events, cardiac intervention) occurred in 196 patients (33%). Median RDW was
13.4 (12.8–14.1)% versus 12.9 (12.5–13.4)% in patients with and without the primary endpoint (P b 0.001).
RDW was signiﬁcantly associated with the endpoint when adjusted for age, sex, clinical risk factors, CRP, and
NT-proBNP (HR 1.20; 95% CI 1.06–1.35; P=0.003). The C-index of the model including RDW was slightly, but
signiﬁcantly (P= 0.005) higher than the model without (0.74, 95% CI 0.70–0.78 versus 0.73, 95% CI 0.69–
0.78). Analysis of repeated RDWmeasurements (n= 2449) did not show an increase in RDWprior to the occur-
rence of the endpoint.
Conclusions:RDW is associatedwith cardiovascular events in patientswith ACHD, independently of age, sex, clin-
ical risk factors, CRP, and NT-proBNP. This readily available biomarker could therefore be considered as an addi-
tive biomarker for risk stratiﬁcation in these patients.
© 2017 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Adult congenital heart disease1. Introduction
Red cell distributionwidth (RDW) is amarker of anisocytosis,which is
automaticallymeasuredwhen a complete blood count is requested. RDW
is calculated as the coefﬁcient of variation of the red cell volume distribu-
tion (standard deviation divided bymean cell volume). A high RDW indi-
cates a greater variation in erythrocyte size, and a low RDW indicates a
more homogeneous population of red blood cells [1]. Various distinct
pathophysiological mechanisms such as impaired iron mobilization,ability and freedom from bias of
edical Center, Department of
rdam, The Netherlands.
elink).
. This is an open access article under
, Red cell distribution width in
Cardiol (2017), https://doi.orineffective erythropoiesis, nutritional deﬁciencies, decreased hemoglobin
level, oxidative stress, and inﬂammation have been related to an in-
creased RDW [2–5].
Interestingly, increased RDWhas been reported to be closely related
to the risk of adverse events in the general population [6,7]. More spe-
ciﬁc, it has been shown to be a predictor of cardiovascular morbidity
and mortality in patients with acute and chronic heart failure [2,8–11],
coronary heart disease [12,13] and pulmonary arterial hypertension
[14]. Even an increase in RDW during hospitalization has been related
to adverse outcome [15]. Despite these promising data, its current role
in clinical practice still pertains to the differential diagnosis of anemia
together with the mean cell volume, which was already described in
1983 [16,17].
The number of patients with adult congenital heart disease (ACHD)
is rapidly increasing and although many of these patients have nothe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
adults with congenital heart disease: A worldwide available and low-
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terventions is high. Prognostication is an essential component of the
routine clinical care of patients with ACHD, and forms the basis of pa-
tient information, follow-up management and therapeutic strategies.
To our knowledge, it is unknown whether RDW can enhance the prog-
nostication of ACHD patients. The aim of this study was therefore to in-
vestigate the association between RDW and cardiovascular events in
patients with ACHD. In addition, we evaluated repeated measurements
to investigate the changes in RDW level over time.
2. Methods
2.1. Study design and population
This is a prospective cohort study.We included consecutive adults with amoderate or
complex type of congenital heart defect [18], who routinely visited our ACHD outpatient
clinic with an echocardiogram between April 2011 and April 2013. We excluded patients
with age b 18 years, pregnancy, a mild cardiac lesion (isolated atrial or ventricular septal
defect), not capable of understanding and signing informed consent, or severe kidney
disease (estimated glomerular ﬁltration rate b 30 mL/min at baseline). At the day of
study inclusion, patients underwent physical examination by a cardiologist, 12-lead elec-
trocardiography, echocardiography and venous blood sampling. All patients were struc-
turally followed-up during four years by annual visits to the ACHD outpatient clinic,
including physical examination by a cardiologist, 12-lead electrocardiography, venous
blood sampling, and echocardiography (every two years). During the follow-up, patients
were treated in accordance with ESC guidelines [19].The study protocol was approved
by the Erasmus MC medical ethics committee and all participants provided written in-
formed consent. Other details of the study protocol and the echocardiographic image anal-
ysis have been described previously [20,21].
2.2. Laboratory measurements
An automated complete blood countwas performed in fresh K2EDTA plasma samples
at study inclusion and at the planned yearly follow-up visits in the clinical chemistry lab-
oratory of the Erasmus MC, using a Sysmex XN-1000™ Hematology Analyzer (Sysmex
Europe GmbH, Norderstedt, Germany). Up to ﬁve subsequent annual measurements per
patient were collected. Samples were stored at room temperature and were analyzed
within 3 h of collection. RDW measurements were performed for research purposes
only, and decisions regarding patient management were made independently of RDW
measurements. The lower and upper limits of normal for RDW in our lab are 12.0
and 16.0%, respectively. Anemia was deﬁned as a hemoglobin level of b139 g/L in men
(b8.6 mmol/L) and b121 g/L (b7.5 mmol/L) in women. N-terminal pro-B-type natriuretic
peptide (NT-proBNP) was directly measured in fresh serum samples, using a commercial
electrochemiluminescence immunoassay (Roche Diagnostics, Rotkreuz, Switzerland).
More details have been published previously [21].
2.3. Deﬁnition and assessment of events
We deﬁned the primary endpoint prior to the collection of data as a composite of the
following (cardiovascular) events: all-causemortality, heart failure (requiring initiation or
change in heart failure medication, or requiring hospital admission), hospitalization for
cardiac reasons, arrhythmia (symptomatic and recorded, or requiring treatment), throm-
boembolic events (ischemic cerebrovascular accident, pulmonary embolism or myocar-
dial infarction), and/or cardiac interventions (surgical or percutaneous). The secondary
endpoint was deﬁned as a composite of all-cause mortality and/or heart failure.
According to the study protocol, patientswere followed for the occurrence of fatal and
non-fatal events by a yearly clinical evaluation at our institution. The end of the follow-up
period was set on August 1, 2016. Survival status was also checked in the Municipal
Population Register. Suspect endpoint events were adjudicated by two experienced inves-
tigators (VB and JR) without knowledge of RDW levels.
2.4. Statistical analysis
Patient characteristics were described per quartile of the RDW distribution. Depend-
ing on the data distribution, thesewere presented asmean± standard deviation or asme-
dian [interquartile range (IQR)]. Comparisons across quartiles of the RDW distribution
were performed using the Chi-SquareMantel-Haenszel test for trend (for categorical var-
iables) or linear regression (for continuous variables).
For patients with multiple events, event-free survival was deﬁned as the time from
enrollment to the occurrence of the ﬁrst event. Patients without any cardiovascular
event were censored at the end of the follow-up duration. Kaplan-Meier endpoint-free
survival curveswere presented for each RDWquartile separately. Cox regressionwas per-
formed to investigate the association between baseline RDWand study endpoints.We an-
alyzed RDW both as a categorical variable (in quartiles) and as a continuous variable
(RDWwas normally distributed and presented per % increase). We also investigated the
association of the other components of the automated blood count (hemoglobin, hemat-
ocrit and mean cell volume) with the primary and secondary endpoint. Associations
were adjusted for age, sex, congenital diagnosis, cardiac medication use, NYHA class,Please cite this article as: V.J.M. Baggen, et al., Red cell distribution width in
cost predictor of cardiovascular events, Int J Cardiol (2017), https://doi.orrhythm, and systemic ventricular function. Furthermore, we performed additional adjust-
ment for C-reactive protein andNT-proBNP. Data onNT-proBNPwas99% complete; impu-
tation of the mean was used to account for missing data. All other covariates were 100%
complete. We reported crude and adjusted hazard ratios (HR) and their corresponding
95% conﬁdence intervals (CI).
In order to evaluate the potential added value of RDW for risk prediction, we deter-
mined C-statistics of models with and without RDW as a predictor. Models were com-
pared using the likelihood ratio test [22].
We developed linear mixed-effects (LME) models to analyze the temporal pattern of
RDW throughout the follow-up, while accounting for the correlation between subsequent
RDWmeasurements within individuals. The correlations in the repeated RDWmeasure-
ments were modeled using a random intercept and a linear random slopes term.
Within-subject variation was expressed as residual variance / total variance ∗ 100%.
Between-subject variation calculated as (total variance− residual variance) / total
variance ∗ 100%. We evaluated differences in temporal evolvement of RDW between pa-
tients with and without the study endpoints by LME models including a time ∗ endpoint
interaction term in the ﬁxed part of the model. Because the temporal RDW evolution
was similar in patientswith andwithout study endpoints, we did not apply jointmodeling
to obtain hazard ratios for these relations.
Data analysis was performed using IBM SPSS Statistics for Windows, version 21.0
(IBM Corp., Armonk, NY, USA) and using the survC1, nlme and JMBayes packages in R sta-
tistical software, version 3.3.2 (available at: www.r-project.org) [23,24]. Two-sided P-
values b 0.05 were considered statistically signiﬁcant.
3. Results
3.1. Study cohort
Of the 602 patients with moderate to complex ACHD who were in-
cluded in the cohort, a baseline RDW measurement was available in
592 patients. None of the patients had to be excluded because of severe
kidney disease at baseline. Themedian age at inclusionwas 33 [IQR 25–
41] years and 342 (58%) were male. Surgical repair was performed in
537 patients (91%) at young age (3.8 [IQR 0.8–11.9] years). Themajority
of patients were in NYHA class I (90%). Anemia was present in 28 pa-
tients (5%). Other baseline characteristics are described in Table 1.
3.2. Association of RDW with patient characteristics
Median RDWwas 13.1 [IQR 12.7–13.7, range 11.3–20.7]%. The ma-
jority of baseline RDW measurements was within the normal range:
only 17 patients (3%) had a RDW b12.0% and only 15 patients (3%)
had a RDW N16.0%. In the highest RDW quartile, patients were signiﬁ-
cantly older and underwent surgical repair at an older age. Moreover,
a larger proportion was female, had a complex congenital diagnosis,
used cardiac medication, had a low oxygen saturation and was in
NYHA class II-III. In addition, in the highest RDW quartile a larger pro-
portion of patients had loss of sinus rhythm, and patients had a worse
systemic ventricular function and higher NT-proBNP levels. Baseline
characteristics across quartiles of RDW distribution are further detailed
in Table 1. RDW levels were higher in patients with pulmonary hyper-
tension, a functionally univenticular heart or a congenitally corrected
transposition of the great arteries (Supplemental File 1).
3.3. Follow-up
Survival status according to the Municipal Population Register and
detailed follow-up data regarding non-fatal events were available in
588patients (99.3%). After amedian of 4.3 [3.8–4.7] years of prospective
follow-up, the primary endpoint occurred in 196 patients (33%) and the
secondary endpoint occurred in 57 patients (10%). The components of
the primary endpoint are separately displayed in Table 2.
3.4. Relation between baseline RDW and study endpoints
Median RDWwas 13.4 (12.8–14.1)% versus 12.9 (12.5–13.4)% in pa-
tients with and without the primary endpoint, respectively (P b 0.001).
Median RDW was 13.9 (13.4–15.0)% versus 12.9 (12.5–13.5)% in
patients with and without the secondary endpoint, respectivelyadults with congenital heart disease: A worldwide available and low-
g/10.1016/j.ijcard.2018.02.118
Table 1
Baseline characteristics of the study population.
Baseline RDW quartiles (n = 592)
All (n = 592) Q1 (b12.7%, n = 173) Q2 (12.7–13.1%, n = 137) Q3 (13.1–13.7%, n = 149) Q4 (≥13.7%, n = 133) P for trend
Clinical characteristics
Age, years 33 [25–41] 31 [24–39] 30 [23–39] 33 [26–45] 37 [28–48] b0.001
Sex, male, n (%) 342 (58) 112 (65) 85 (62) 88 (59) 57 (43) b0.001
Surgical repair, n (%) 537 (91) 156 (90) 123 (90) 133 (89) 125 (94) 0.349
Age at surgical repair, years 3.8 [0.8–11.9] 1.9 [0.5–9.2] 2.8 [0.5–11.7] 4.2 [1.2–12.8] 7.4 [2.6–17.8] b0.001
Congenital diagnosis, n (%)a 318 (54) 90 (52) 57 (42) 83 (56) 88 (66) 0.004
Cardiac medication use, n (%) 211 (36) 36 (21) 35 (26) 65 (44) 75 (56) b0.001
Body mass index, kg/m2 24.8 ± 4.4 24.1 ± 3.7 24.8 ± 4.2 24.6 ± 4.3 25.8 ± 5.2 0.001
Heart rate, beats/min 74 ± 13 73 ± 14 73 ± 13 73 ± 13 75 ± 13 0.165
Systolic blood pressure, mm Hg 126 ± 16 127 ± 15 126 ± 15 126 ± 15 126 ± 20 0.619
O2 saturation b 90%, n (%) 17 (3) 2 (1) 0 (0) 1 (1) 14 (11) b0.001
NYHA class, II-III, n (%) 59 (10) 7 (4) 4 (3) 17 (11) 31 (23) b0.001
Electrocardiogram
Rhythm, n (%) b0.001
Sinus rhythm 514 (87) 161 (93) 125 (91) 123 (83) 105 (79)
Paced rhythm 43 (7) 6 (3) 6 (4) 17 (11) 14 (11)
Other 35 (6) 6 (3) 6 (4) 9 (6) 14 (11)
QRS duration, ms 112 [99–137] 112 [102–137] 106 [96–126] 114 [100–147] 118 [98–141] 0.205
Echocardiogram
LA volume, mL/m2b 21 [16–29] 20 [14–27] 20 [15–30] 21 [15–28] 24 [19–40] b0.001
LV end-diastolic volume, mL/m2b 64 ± 19 63 ± 16 65 ± 18 62 ± 19 63 ± 22 0.733
LV ejection fraction, %b 56 ± 8 57 ± 6 56 ± 8 56 ± 8 55 ± 10 0.119
RV end-diastolic annulus, mm 42 ± 8 42 ± 8 41 ± 8 42 ± 9 44 ± 9 0.104
RV fractional area change, % 38 ± 11 39 ± 11 38 ± 11 38 ± 12 37 ± 13 0.338
Systemic ventricular function, n (%) b0.001
Normal 299 (51) 94 (54) 81 (59) 66 (44) 58 (44)
Mildly impaired 208 (35) 63 (36) 39 (28) 58 (39) 48 (36)
Moderately impaired 67 (11) 15 (9) 15 (11) 17 (11) 20 (15)
Severely impaired 18 (3) 1 (1) 2 (2) 8 (5) 7 (5)
E/A ratio 1.6 ± 0.7 1.8 ± 0.7 1.7 ± 0.7 1.5 ± 0.6 1.5 ± 0.6 0.001
E' wave, cm/s 8.3 ± 2.7 8.8 ± 2.8 8.6 ± 2.7 8.1 ± 2.4 7.2 ± 2.5 b0.001
E/E' ratio 11.6 ± 5.1 11.1 ± 4.4 10.8 ± 4.8 11.3 ± 4.2 13.7 ± 6.7 0.001
Laboratory results
Hemoglobin, g/Lc 149 ± 16 151 ± 11 149 ± 12 149 ± 14 145 ± 24 0.003
Hematocrit, L/L 0.44 ± 0.04 0.44 ± 0.03 0.44 ± 0.03 0.44 ± 0.03 0.44 ± 0.06 0.381
Mean cell volume, fL 88 ± 5 88 ± 4 88 ± 4 88 ± 4 87 ± 7 0.077
Creatinine, μmol/L 77 ± 18 77 ± 13 77 ± 15 75 ± 14 79 ± 28 0.432
eGFR, mL/min 90 [82–90] 90 [85–90] 90 [84–90] 90 [82–90] 87 [75–90] b0.001
C-reactive protein, mg/L 1.5 [0.6–3.5] 1.0 [0.5–2.5] 1.3 [0.5–3.3] 1.3 [0.5–3.4] 2.5 [1.3–6.3] b0.001
Total cholesterol, mmol/L 4.8 ± 1.0 4.6 ± 0.9 4.8 ± 0.9 4.9 ± 1.1 4.8 ± 1.1 0.050
Low density lipoprotein, mmol/L 3.0 ± 0.9 2.8 ± 0.8 3.0 ± 0.8 3.1 ± 1.0 3.0 ± 1.0 0.032
NT-proBNP, pmol/L 15.0 [6.8–33.4] 10.1 [5.5–21.7] 11.7 [5.2–27.3] 16.6 [7.9–31.3] 31.1 [11.9–70.8] b0.001
Legend: Values are reported as median [IQR], otherwise as n (%) ormean± SD. Differences across baseline RDWquartiles are analyzed using the Chi-SquareMantel-Haenszel test for cat-
egorical variables, otherwise using linear regression.
Abbreviations: ACE, angiotensin convertingenzyme; ARBs, angiotensin receptor blockers; eGFR, estimated glomerularﬁltration rate; LA, left atrial; LV, left ventricular; NT-proBNP,N-terminal
pro-B-type natriuretic peptide; NYHA, New York Heart Association; RDW, Red blood cell distribution width; RV, right ventricular.
a Congenital diagnosis of aortic stenosis, aortic coarctation or arterial switch operation (0) versus tetralogy of Fallot, Rastelli, systemic RV, univentricular heart or pulmonary
arterial hypertension [1].
b Left sided volumes were not measured in patients with a systemic right ventricle, functionally univentricular heart, pulmonary hypertension (n= 137) or a poor acoustic window.
c Hemoglobin was converted frommmol/L to g/L by using the conversion factor 0.06202.
3V.J.M. Baggen et al. / International Journal of Cardiology xxx (2017) xxx–xxx(P b 0.001). The cumulative RDW distribution in patients with and
without study endpoints is depicted in Supplemental File 2.
Patients who were in a higher RDW quartile had a signiﬁcantly
lower primary and secondary endpoint-free survival, as is shown in
the Kaplan-Meier curves in Fig. 1. When the RDW quartiles were ana-
lyzed in a multivariable Cox model including multiple clinical variables,
C-reactive protein, and NT-proBNP, the association was partially atten-
uated but remained statistically signiﬁcant. Moreover, each separate
component of the primary endpoint seemed to occur more frequently
in patients in the highest RDW quartile (Table 2). As is shown in
Table 3, similar conclusions were found when RDW was analyzed as a
continuous variable. None of the other components of the automated
blood count (hemoglobin, hematocrit andmean cell volume) were pre-
dictive of the primary endpoint; however, a decreased hemoglobin was
signiﬁcantly associated with the secondary endpoint. We therefore
conducted sensitivity analyses with additional adjustment of thePlease cite this article as: V.J.M. Baggen, et al., Red cell distribution width in
cost predictor of cardiovascular events, Int J Cardiol (2017), https://doi.orassociations between RDW and study endpoints for hemoglobin,
which did not yield different conclusions.
A basic risk marker model including age, sex, congenital diagnosis,
cardiac medication use, NYHA class, rhythm, systemic ventricular func-
tion, andNT-proBNPyielded a C-index of 0.73 (95% CI 0.69–0.78) for the
primary endpoint. The augmentedmodelwith RDW included as predic-
tor yielded a C-index of 0.74 (95% CI 0.70–0.78), which was a modest
but signiﬁcant improvement (P=0.005).
3.5. Repeated RDW measurements
During the follow-up, a total of 2449 RDWmeasurements were col-
lected. Although the majority of the RDW measurements (n = 2085,
85%) were in the normal range, the RDWwas clearly and consequently
higher at baseline and throughout the entire follow-up duration in pa-
tients with a primary endpoint, compared with patients who remainedadults with congenital heart disease: A worldwide available and low-
g/10.1016/j.ijcard.2018.02.118
Table 2
Risk of the primary composite endpoint (cardiovascular event) and secondary composite endpoint (death or heart failure) according to baseline RDW quartiles.
RDW quartiles (n = 592)
All (n = 592) Q1 (b12.7%, n = 173) Q2 (12.7–13.1%, n = 137) Q3 (13.1–13.7%, n = 149) Q4 (≥13.7%, n = 133) P for trenda
Cardiovascular event
No. Cases 196 34 34 55 73
Person-years 1966 620 504 473 369
Crude HR (95% CI) Reference 1.24 (0.77–1.99) 2.10 (1.37–3.22) 3.48 (2.32–5.23) b0.001
Adjusted HR (95% CI)b Reference 1.23 (0.77–1.99) 1.49 (0.99–2.32) 2.13 (1.38–3.30) b0.001
Adjusted HR (95% CI)c Reference 1.14 (0.71–1.84) 1.44 (0.92–2.24) 1.76 (1.12–2.76) 0.009
Death or heart failure
No. Cases 57 3 4 14 36
Person-years 2338 690 585 590 472
Crude HR (95% CI) Reference 1.61 (0.36–7.20) 5.51 (1.58–19.2) 17.4 (5.35–56.5) b0.001
Adjusted HR (95% CI)b Reference 1.48 (0.33–6.66) 2.37 (0.66–8.44) 5.34 (1.58–18.1) b0.001
Adjusted HR (95% CI)c Reference 1.15 (0.25–5.25) 2.27 (0.64–8.08) 3.48 (1.00–12.1) 0.008
No. cases (detailed)d
Death 16 1 2 2 11 \\
Heart failure 51 2 3 12 34 \\
Hospitalization 150 26 27 39 58 \\
Arrhythmia 109 18 17 33 41 \\
Thromboembolic event 24 2 6 8 8 \\
Cardiac intervention 112 23 20 33 36 \\
Abbreviations: CI, conﬁdence interval; HR, hazard ratio; NT-proBNP, N-terminal pro-B-type natriuretic peptide; RDW, red blood cell distribution width.
a Calculated by assigning the median level in each quartile to participants and evaluating this variable continuously.
b Adjusted for age (years), sex, congenital diagnosis (aortic stenosis, aortic coarctation or arterial switch operation (0) versus tetralogy of Fallot, Rastelli, systemic RV or univentricular
heart [1]), cardiac medication use (yes/no), NYHA class II-III, sinus rhythm (yes/no), systemic ventricular function (0–3).
c Additionally adjusted for C-reactive protein and NT-proBNP (both log2-transformed).
d All components of the primary endpoint are separately displayed for exploratory purposes (in which patients were not censored at the time of another endpoint than the endpoint of
interest). No comparisons are made between subgroups, in order to avoid multiplicity of comparisons.
4 V.J.M. Baggen et al. / International Journal of Cardiology xxx (2017) xxx–xxxendpoint-free. This difference was even more pronounced in patients
with the secondary endpoint (Supplemental File 3). In Supplemental
Files 4 and 5, the individual measurements are displayed for each
patient separately. Our data did not provide evidence for a steady in-
crease in RDW prior to the occurrence of adverse events. The largest
part of variation between the RDW measurements was attrib-
utable to between-subject variation (76%) instead of within-subject
variation (24%).4. Discussion
In this study, we have prospectively followed a large cohort of ACHD
patients during 4.3 years with annual repeated RDW measurements.Fig. 1. Kaplan-Meier curves stratiﬁed per baseline RDW quartile for the primary and seconda
quartile.
Please cite this article as: V.J.M. Baggen, et al., Red cell distribution width in
cost predictor of cardiovascular events, Int J Cardiol (2017), https://doi.orRDWwas higher at study inclusion and throughout the entire follow-
up period in patients with a cardiovascular event, especially in patients
who died or developed heart failure. Increased RDW at inclusion was
signiﬁcantly associated with cardiovascular events during follow-up,
independently of NT-proBNP and other prognostic markers. Adding
RDW to a prognostic model including established clinical risk factors
and NT-proBNP yielded a modest improvement.4.1. Previous reports
To our knowledge, this is the ﬁrst large and prospective study that
investigated the prognostic value of RDW in patients with ACHD. The
ﬁndings of this study are in line with previous studies that have beenry endpoint. Legend: Q1, ﬁrst quartile; Q2, second quartile; Q3, third quartile; Q4, fourth
adults with congenital heart disease: A worldwide available and low-
g/10.1016/j.ijcard.2018.02.118
Table 3
Associations between baseline hemoglobin, hematocrit, mean cell volume, and red cell distribution and the primary and secondary endpoint, analyzed continuously.
Crude HR (95% CI) P-value Adjusted HRa (95% CI) P-value Adjusted HRb (95% CI) P-value
Cardiovascular event
Hb, g/L 1.00 (0.99–1.01) 0.572 \\ \\ \\ \\
Ht, L/L 2.15 (0.06–79.3) 0.678 \\ \\ \\ \\
MCV, fL 1.01 (0.98–1.04) 0.551 \\ \\ \\ \\
RDW, % 1.47 (1.34–1.62) b0.001 1.26 (1.13–1.41) b0.001 1.20 (1.06–1.35) 0.003
Death or heart failure
Hb, g/L 0.98 (0.96–1.00) 0.024 0.98 (0.96–1.00) 0.020 0.98 (0.97–1.00) 0.011
Ht, L/L 0.10 (0.00–13.0) 0.209 \\ \\ \\ \\
MCV, fL 0.99 (0.94–1.05) 0.731 \\ \\ \\ \\
RDW, % 1.81 (1.59–2.06) b0.001 1.45 (1.23–1.70) b0.001 1.38 (1.15–1.65) 0.001
Abbreviations: CI, conﬁdence interval; HR, hazard ratio.
a Adjusted for age (years), sex, congenital diagnosis (aortic stenosis, aortic coarctation or arterial switch operatio n (0) versus tetralogy of Fallot, Rastelli, systemic RV or univentricular
heart [1]), cardiac medication use (yes/no), NYHA class II-III, sinus rhythm (yes/no), systemic ventricular function (0–3).
b Additionally adjusted for C-reactive protein and NT-proBNP (both log2-transformed).
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ure and coronary heart disease [2,8–13]. More speciﬁc, in a retrospec-
tive cohort study of Miyamoto et al. in 144 patients with ACHD who
were hospitalized [25], increased RDW was closely related to the risk
of cardiovascular death. Comparable results were found in a retrospec-
tive cohort of 109 adult patients with Eisenmenger syndrome [26]. Fur-
thermore, RDWwas found to be an indicator of iron deﬁciency in adult
Fontan patients and correlated with lower exercise capacity [27]. The
remainder of studies that have been performed in congenital heart dis-
ease have only included pediatric patients. In a small cross-sectional
study of pediatric patients with a Fontan circulation, increased RDW
was related to a higher central venous pressure and a lower mixed ve-
nous oxygen saturation [28]. In addition, preoperative RDW has been
reported to positively correlate with the length of postoperative stay
in children undergoing surgery for congenital heart disease [29,30].4.2. Pathophysiological mechanisms
RDW likely reﬂects a broad range of pathophysiological processes,
that could explain the association between RDW and cardiovascular
events in patients with ACHD. First of all, RDWhas been directly related
tomarkers of impaired ironmobilization, decreased erythropoietin pro-
duction, and nutritional deﬁciencies such as iron, folate, or vitamin B12
[2,3,31]. This may subsequently cause a decreased hemoglobin level,
which is associated with a worse prognosis in chronic heart failure pa-
tients [32,33]. Nevertheless, data from previous studies and also from
our cohort show that RDW provides prognostic information indepen-
dent of hemoglobin level [10].Moreover, only 5%of patients had anemia
in our study.
Young red blood cells are relatively large and variable in size, and the
erythrocytes shrink and become more equally sized during the natural
aging process. Oxidative stress and inﬂammation are both known to de-
crease red blood cell survival [4,5]. The decreased lifespan of the eryth-
rocytes will lead to relatively large amounts of both large and small red
cells, which is reﬂected by an increased RDW [31]. In addition, RDWhas
been related to endothelial function as assessed with ﬂow-mediated di-
latation (as a measure of underlying metabolic derangements), and a
high RDW is more frequently present in patients with kidney failure
[34]. Although in our study the average C-reactive protein, total choles-
terol, low density lipoprotein and estimated glomerular ﬁltration were
within the normal range, RDWseemed to be associatedwith thesemea-
sures of inﬂammation, dyslipidemia and kidney function (Table 1).
The heterogeneity of red blood cell size therefore could be an epi-
phenomenon that reﬂects several miscellaneous mechanisms, which
are related to an individual's prognosis. Previous studies have shown
that risk prediction improves when multiple biomarkers are used to-
gether, that reﬂect distinct pathophysiological mechanisms [21,35].
RDW may combine these different mechanisms in one biomarker, andPlease cite this article as: V.J.M. Baggen, et al., Red cell distribution width in
cost predictor of cardiovascular events, Int J Cardiol (2017), https://doi.orthe red blood cell has therefore been previously proposed as an overall
‘barometer’ of cardiovascular health [2].4.3. Clinical implications
The RDW is directly available as part of the automated blood count,
which is a routine component of standard blood testing. The measure-
ment is easy, inexpensive, rapid, does not require speciﬁc skills or
instrumentation, and is readily available in virtually all clinical laborato-
ries worldwide. In light of the accumulating evidence that emphasizes
the prognostic value of RDW, the clinical role of RDWmay be extended
beyond the boundaries of the differential diagnosis of anemia. RDW
could be a new tool to enhance the prognostication of ACHD patients,
together with other functional, echocardiographic and biochemical
markers, and can be easily implemented in routine clinical care. Accu-
rate identiﬁcation of high-risk patients will enable more intensive
follow-up with hopefully prevention of events in the future, and the
identiﬁcation of low-risk patientswill lead to reassurance, less intensive
follow-up and cost savings.4.4. Study limitations
Changes in RDW during a hospital admission for acute decompen-
sated heart failure have been previously associated with all-cause mor-
tality or readmission for heart failure [15]. In this study with clinically
stable ACHD patients, we did not observe an increase in RDW prior to
the occurrence of adverse events. However, RDW measurements were
performed only once per year in this study. Therefore, it could be hy-
pothesized that repeatedmeasurements should be performedmore fre-
quently in order to ﬁnd an association between recent changes in RDW
and an adverse event.
Imputation of the mean was used to account for the 1% missing NT-
proBNP values. Although in general imputation of the mean could be
considered as a limitation, it is considered acceptable for covariates
with a very low percentage of missing data.
In this cohort, patients with an isolated repaired atrial or ventricular
septal defect were not included, due to the expected low number of
events in these patients. This should be taken into accountwhen extrap-
olating these data to other cohorts of patients with ACHD.5. Conclusions
The RDW is signiﬁcantly associated with cardiovascular events in
patients with ACHD, independently of NT-proBNP and other prognostic
markers. This readily available biomarker, that can be reliablymeasured
worldwide at a low cost, may therefore be a valuable additional tool in
the risk stratiﬁcation of patients with ACHD.adults with congenital heart disease: A worldwide available and low-
g/10.1016/j.ijcard.2018.02.118
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